drugset
drugset / Trial / NCT05362409

Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

NCT05362409 ↗

Phase 1 Completed 22 enrolled Alpheus Medical, Inc.
NaSequentialOpen-labelTreatment

Summary

A Phase 1 Multi-center clinical Trial Evaluating the Safety and Tolerability of 5-aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With recurrent High Grade Glioma (HGG).

Timeline

Start
2022-06-29
Primary completion
2024-12-03
Completion
2025-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 mg/kg Oral

Indications

malignant glioma